1  on day 5 at 5 microg/kg/d until recovery of granulocyte count.

2 ly depressed peripheral white blood cell and granulocyte counts.

3 ) cyclins (D1, D2, E1, or E2) display normal granulocyte counts.

4 chieved targeted neutropenia (nadir absolute granulocyte count, 100 to 1,000/microL) without any othe

5  less, creatinine level less than 2.0 mg/dL, granulocyte count (AGC) 1,500/microL or greater, platele

6 h day 19 of each cycle or until the absolute granulocyte count (AGC) was > or = 500/microliter on 2 c

7                    The median nadir absolute granulocyte count (AGC) was 1,500/microL.

8 g on day 6 and continuing until the absolute granulocyte count (AGC) was greater than 10,000/microL.

9 creases in the clinical white blood cell and granulocyte count and is a well-documented effect of glu

10 ex (OMI), speed of engraftment (platelet and granulocyte counts), and bilirubin.

11 nd CD36 receptors, also increased peritoneal granulocyte counts, as well as reduced peritoneal bacter

12             Basal total white blood cell and granulocyte counts did not appreciably differ between PM

13 ntoxication suppressed the increase in blood granulocyte counts following intrapulmonary challenge wi

14 gh-dose CEC, the median time from AuBMT to a granulocyte count > or = 0.5/microL was 11 days (range,

15 ance status of 0 to 2, pretreatment absolute granulocyte count > or = 1,500/microL, and platelet coun

16                      Doses were modified for granulocyte counts less than 1,800/microL or neurotoxici

17                         The median time to a granulocyte count more than 500/dL was 19 days (range, 1

18                                   A baseline granulocyte count of more than 1000 cells/microL was pro

19 reatinine concentration (P = 0.008), and low granulocyte count (P = 0.003) as risk factors for infect

20 ession and age, sex, white blood cell count, granulocyte count, the presence of additional cytogeneti